erdafitinib,docetaxel,vinflunine,pembrolizumab,cetrelimab
pierre fabre,merck,janssen
['erdafitinib', 'norse', 'erda ', 'thor study']
norse trial (n=90) compares erdafitinib (fgfri) +pd1 vs erdafitinib alone in fgfr+ves. rrs: 55% vs 45%. pd1i effect due to pd-l1 +ve (5%). the addition of pd1 is uncertain here. rr of 45% for erda reinforces the impressive results of the thor study (45%) #asco2023 
Interested in Urology Cancers, biomarkers and drug development.